Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test could spot kidney patients at risk of failure

NCT ID NCT02199145

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a new blood test that measures specific antibodies in people with membranous nephropathy, an autoimmune kidney disease. The test aims to predict which patients are more likely to develop kidney failure. Researchers will follow 52 adults over time to see if the test results match their actual kidney health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this test could help doctors identify which membranous nephropathy patients are at highest risk of kidney failure, allowing earlier and more targeted treatment.
What could go wrong
This is a small, early-stage study with only 52 participants. The test needs confirmation in larger, more diverse groups before it can be used in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

52 people

The number who actually took part.

Started

Jul 2015

Finished

Jun 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients * Patients with MN stade I-II confirmed by kidney biopsy * Patients with MDRD\>30 ml/mn/1.73m2 * Patients with anti-PLA2R1 antibodies * Effective Contraception for women of childbearing age Exclusion Criteria: * Patients minors * Patients refusing to participate in the study * Patients with secondary MN (systemic Lupus, hepatitis B virus, hepatitis C virus or cancer) * Pregnant women: a urine pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a doctor of his choice. * Persons deprived of liberty (administrative or judicial) * Persons under guardianship * People may not understand the research * Persons under guardianship, under judicial protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Membranous nephropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Membranous nephropathy

Contacts and locations

Locations

  • AP-HM

    Marseille, 13354, France

  • CHU de Besançon

    Besançon, France

  • Nephrology Department, Nice University Hospital

    Nice, 06003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.